EP 2634185;
INTERLEUKIN 23;
JANUS KINASE 1;
JANUS KINASE 2;
JANUS KINASE 3;
PROTEIN TYROSINE KINASE INHIBITOR;
UNCLASSIFIED DRUG;
WO 2013125543;
WO 2013146963;
ALDOL REACTION;
AMINATION;
ARTICLE;
BROMINATION;
DRUG BIOAVAILABILITY;
DRUG DEVELOPMENT;
DRUG HALF LIFE;
DRUG SCREENING;
DRUG SELECTIVITY;
EVALUATION STUDY;
HYDROLYSIS;
IC 50;
MULTIPLE SCLEROSIS;
NONHUMAN;
SUZUKI REACTION;
ANIMALS;
ANTI-INFLAMMATORY AGENTS;
AUTOIMMUNE DISEASES;
DISEASE MODELS, ANIMAL;
HUMANS;
INFLAMMATION;
LEGISLATION, DRUG;
MOLECULAR STRUCTURE;
PATENTS AS TOPIC;
PROTEIN KINASE INHIBITORS;
SIGNAL TRANSDUCTION;
STRUCTURE-ACTIVITY RELATIONSHIP;
TYK2 KINASE;
Jakinibs: A new class of kinase inhibitors in cancer and autoimmune disease
Recent state of the art of review on the utility of this kinase family
Kontzias A, Kotlyar A, Laurence A, et al. Jakinibs: A new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 2012;12(4):464-70.. Recent state of the art of review on the utility of this kinase family.
Advances in the discovery of selective JAK inhibitors
Review focusing on JAK inhibitors
Menet CJ, Rompaey LV, Geney R. Advances in the discovery of selective JAK inhibitors. Prog Med Chem 2013;52:153-223. Review focusing on JAK inhibitors.
Selective JAK1 inhibitor and selective Tyk2 inhibitor patents
Highlights the paucity of patents claiming Tyk2 inhibitors
Norman P. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents. Expert Opin Ther Pat 2012;22(10):1233-49.. Highlights the paucity of patents claiming Tyk2 inhibitors.
Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors
Detailed description of the Genentech effort
Liang J, Van Abbema A, Balazs M, et al. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. J Med Chem 2013;56(11):4521-36.. Detailed description of the Genentech effort.
A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors
First detailed biological study with selective Tyk2 inhibitors
Sohn SJ, Barrett K, Van Abbema A, et al. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol 2013;191(5):2205-16.. First detailed biological study with selective Tyk2 inhibitors.
Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor
Argiriadi MA, Goedken ER, Banach D, et al. Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor. BMC Struct Biol 2012;12:22
Sareum Holdings plc Press Release 22 April Available from
Sareum Holdings plc. SAREUM and SRI international announce agreement to advance development of tyrosine kinase 2 inhibitors for treatment of autoimmune and inflammatory diseases. Press Release 22 April 2013 Available from: Http://www.sareum.co.uk/pressreleases.phpnewsid=185&year=-1
